Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestationsJan‐Niklas Eckardt, Jan Moritz Middeke, Friedrich Stölzel et al.|Journal of Hematology & Oncology|2022Cited by 58
Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learningJan‐Niklas Eckardt, Jan Moritz Middeke, Christoph Röllig et al.|Haematologica|2022Cited by 47
Differential impact of <i>IDH1</i>/<i>2</i> mutational subclasses on outcome in adult AML: results from a large multicenter studyJan Moritz Middeke, Christian Thiede, Klaus H. Metzeler et al.|Blood Advances|2021Cited by 44
Overlapping features of therapy-related and de novo <i>NPM1</i>-mutated AMLJad Othman, Brunangelo Falini, Bjørn Tore Gjertsen et al.|Blood|2022Cited by 43
Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classificationJan‐Niklas Eckardt, Christoph Röllig, Marius Bill et al.|Leukemia|2023Cited by 36